1160 related articles for article (PubMed ID: 15536460)
1. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
2. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Kharasch ED; Hoffer C; Walker A; Sheffels P
Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
[TBL] [Abstract][Full Text] [Related]
3. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
5. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Kharasch ED; Francis A; London A; Frey K; Kim T; Blood J
Clin Pharmacol Ther; 2011 Jul; 90(1):100-8. PubMed ID: 21562488
[TBL] [Abstract][Full Text] [Related]
8. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Phimmasone S; Kharasch ED
Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
[TBL] [Abstract][Full Text] [Related]
9. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Kharasch ED; Whittington D; Hoffer C
Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
[TBL] [Abstract][Full Text] [Related]
10. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
12. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
13. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
14. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Ibrahim AE; Feldman J; Karim A; Kharasch ED
Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
[TBL] [Abstract][Full Text] [Related]
16. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Kharasch ED; Vangveravong S; Buck N; London A; Kim T; Blood J; Mach RH
Clin Pharmacol Ther; 2011 Apr; 89(4):562-70. PubMed ID: 21346758
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
18. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.
Liangpunsakul S; Kolwankar D; Pinto A; Gorski JC; Hall SD; Chalasani N
Hepatology; 2005 May; 41(5):1144-50. PubMed ID: 15841467
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
[TBL] [Abstract][Full Text] [Related]
20. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]